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Operative Intervention Does Not Change Pain
Perception in Patients With Diabetic Foot Ulcers
Olivia V. Waldman,1* Stephanie P. Hao,1* Jeff R. Houck,2 Nicolette J. Lee,3 Judith F. Baumhauer,1 and Irvin Oh1

Researchers investigated pain perception in patients
with diabetic foot ulcers (DFUs) by analyzing pre- and
postoperative physical function (PF), pain interference
(PI), and depression domains of the Patient-Reported
Outcome Measurement Information System (PROMIS).
They hypothesized that 1) because of painful diabetic
peripheral neuropathy (DPN), a majority of patients
with DFUs would have high PROMIS PI scores
unchanged by operative intervention, and 2) the initially
assessed PI, PF, and depression levels would be
correlated with ﬁnal outcomes. Seventy-ﬁve percent of
patients with DFUs reported pain, most likely because
of painful DPN. Those who reported high PI and low PF
were likely to report depression. PF, PI, and
depression levels were unchanged after operative
intervention or healing of DFUs.
Diabetic foot ulcers (DFUs) are a debilitating and common
side effect of diabetes, experienced by up to 25% of
people with diabetes (1–3). Foot ulceration is caused by a
combination of internal and external risk factors that lead
to the breakdown of skin, resulting in an exposed wound
that can quickly become infected (2). Repetitive trauma or
pressure in an insensate foot due to diabetic peripheral
neuropathy (DPN) is the most common cause of DFUs,
which can present with numbness, pain, or weakness
(1,2). Some patients with DFUs report foot numbness
without pain, whereas some report a signiﬁcant amount
of pain that affects clinical care. An estimated 10–20%
of all people with diabetes experience painful DPN,
which can occur with or without the presence of a DFU
and at any stage in the disease (4–6). In such cases, DPN
pain can result in lower reported quality of life and
carries a doubled risk of depression in patients with
diabetes (1,4,7,8).

Because of varying symptoms and extent of infection,
understanding the nature of a DFU patient’s pain can be
challenging for clinicians. Although many patients with
DFUs expect decreased pain after successful treatment
and healing of their ulcer, persistent pain after healing is
prevalent (9).
Meanwhile, nontherapeutic opioid use has become a
public health crisis, especially in the United States, where
80% of the global opioid supply is consumed (10). The
opioid abuse epidemic that has enveloped the United
States has not been slowing with awareness, but rather
has increased threefold in recent years (10).
The Patient-Reported Outcomes Measurement Information System (PROMIS) is a patient health measurement
instrument that has been funded by the National Institutes
of Health since 2004. Studies have shown that PROMIS
accurately reports changes in patient-reported conditions
(11,12). Among various domains of PROMIS, the physical
function (PF), pain interference (PI), and depression
scales have been widely used in medicine (13). PROMIS
has been identiﬁed as a more reliable measurement than
the Numeric Pain Rating Scale (NPRS), the Foot and
Ankle Ability Measure, and the Foot Function in Index in
assessing foot and ankle pain and can beneﬁt patient care,
research, and communication (14,15). The PROMIS PI
scale especially has been demonstrated to be superior to
the NPRS in assessing pain levels in foot and ankle patients
(14). PROMIS uses item response theory and computerized adaptive testing (CAT) to yield a high level of
precision and speciﬁcity with the fewest responses
required from patients (11,16,17). The questions are
designed to be readable by individuals of various education levels to promote accuracy in a diverse patient
population (18). Despite the widespread use of PROMIS,
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there has been no report of this tool being used to assess
pain experienced by patients with DFUs. Accurate understanding of the nature of diabetic foot pain and how it
changes with operative intervention for DFUs will help
clinicians effectively manage, educate, and set expectations of patients regarding perioperative pain.
This study aimed to assess changes in pain intensity
associated with operative intervention in DFU patients
using the PROMIS PI domain and to investigate clinical
factors that may inﬂuence pain perception. We hypothesized that 1) patients with DFUs would experience higher
levels of PI and depression and lower PF than the average
U.S. population; 2) PI, PF, and depression scores would
not change signiﬁcantly after operative intervention; and
3) PI, PF, and depression would be correlated. In particular, we hypothesized that the combination of worse PF
and PI compared with the general U.S. population would
be correlated to more severe depression.

monoﬁlament test, were conducted to diagnose or document the presence of DPN (1,3,6).

Statistical Analyses
Descriptive statistical analyses were conducted for patient
factors, clinical variables, and PROMIS scores (PF, PI, and
depression scales).
Severity of symptoms deﬁned by the PROMIS scales were
determined by calculating the proportion of patients in
standard deviation (SD) increments above and below the
U.S. averages (T-score 50) (hypothesis 1). The categories
included at or better than (.0) the U.S. average (score 5 0),
1 SD worse (0 to –9.99) than the U.S. average (score 5 –1), 2
SDs worse (–10 to –19.99) than the U.S. average (score 5
–2), 3 SDs worse (–20 to –29.99) than the U.S. average
(score 5 –3), and .3 SDs worse (230 or lower) than the
U.S. average (score 5 –4). This calculation resulted in each

Research Design and Methods
Participants
Data collection was conducted in a single academic orthopedic surgeon’s practice from February 2015 to November 2018. A total of 240 patients who underwent
operative intervention of an infected DFU during this time
period were identiﬁed using code E11.621 from the International Statistical Classiﬁcation of Diseases and Related
Health Problems, 10th revision (ICD-10). Patients were
excluded from the study if they had fewer than three
PROMIS assessments or incomplete PROMIS data, if their
postoperative follow-up was ,3 months, or they had
recurrent infections within 3 months. Ninety-two patients
met the inclusion criteria for this study, and their data were
used to quantify PROMIS domain changes and make
minimal clinically important difference (MCID) calculations from their initial visits to their ﬁnal follow-up visits
(Figure 1). An additional 19 patients were followed up
for ,3 months but met all other inclusion criteria. Patient
demographics were calculated and x2 analysis of scores
from the initial visits was performed using patient data
from the combined total (n 5 111).
PROMIS assessments considered complete included
PROMIS CAT PI (version 1.1), PROMIS CAT PF (version
2.0), and PROMIS CAT depression (version 1.0) scales
(19–21). They were completed by patients in the clinic’s
waiting area before scheduled visits. Demographic data,
BMI, A1C, presence of chronic renal failure (CRF), type of
amputation, and wound healing information were collected during follow-up appointments. Thorough chart
reviews and physical exams, such as the 5.07 (10G)

FIGURE 1 Patient selection ﬂowchart.

PROMIS scale being converted to an ordinal scale varying
from 0 to –4 to assess symptom severity.
To determine the association of clinical variables with
symptom severity, clinical variables were coded as follows: glycemic control: A1C .7% 5 1, A1C $7% 5 0;
renal function: CRF present 5 1, CRF absent 5 0; type of
surgical intervention: irrigation and debridement 5 0,
forefoot (toe or ray) amputation 5 1, mid/hind foot
(Lisfranc, chopart, or calcanectomy) amputation 5 2,
Syme or above amputation 5 3; and ulcer healing status:
healed 5 1, not healed 5 0. Each of these clinical variables
was assessed for association with symptom severity using
x2 analysis.
Changes in clinical variables and PROMIS scores were
evaluated using T-scores to calculate the proportions of
patients achieving and not achieving an MCID. After
evaluating normality (all PROMIS scales skewness and
kurtosis were ,2.0), changes in PROMIS scores (PF, PI,
and depression) from the initial visit to the longest followup visit were calculated using paired t tests to test our
second hypothesis. To further evaluate change in
symptoms from the initial visit to longest follow-up, the
proportions of patients with improvement in MCID, deterioration in MCID, and change in MCID were calculated
for each PROMIS scale. Improvement in MCID is well
discussed in PF and PI studies (22,23). Values for MCID
improvement range from 3 to .5 T-score points (22,23).
This study used 4 T-score points to determine an MCID
improvement or deterioration, recognizing that future
studies may further modify estimates of deterioration or
improvement depending on their choice of MCID.
To assess the co-occurrence of symptoms deﬁned by the
PROMIS scales, Spearman correlations and x2 analyses
were used. Spearman r statistics were used to calculate
the correlation among PROMIS T-score values at the
initial visit and among PROMIS score changes from the
initial visit to the longest follow-up. Similar to prior
studies using the PROMIS (14), correlation strengths
were categorized as follows: strong ($0.7), strongmoderate (0.61–0.69), moderate (0.4–0.6), moderatepoor (0.31–0.39), or poor (#0.3).
To determine the association of symptom severity, 2 3 2
tables were analyzed using x2 statistics from the initial
PROMIS assessments and for MCID categories of change.
To assess the combined inﬂuence of PROMIS PF and PI
on depression, a composite score was used similar to a
recent study (24). PROMIS PF and PI were summed to
create a composite variable; the summed PF and PI score
from initial PROMIS assessments ranged from –8 to 0.
The

summed PF and PI MCID categories ranged from –2 t o 2 .
Examining the summed PF and PI from the initial PROMIS
assessments and change scores allowed the evaluation of
the combined severity of symptoms associated with depression (hypothesis #3). All analyses were done with
SPSS version 25.0 software.

Results
Patient Characteristics
At the initial visit, 111 participants had data available,
including 92 participants with a minimum of 3 months of
postoperative follow-up (Table 1). For both samples, the
majority were male (79.3 and 80.4%, respectively) with
a mean age of 62.2 and 60.5 years and a mean BMI of
33.8 and 34.1 kg/m2, respectively. The mean follow-up
du-ration was 4.7 months (range 3–12) (Table 1).
Operative procedures performed included irrigation and
debride-ment (n 5 39), forefoot amputations (n 5 46),
mid/hindfoot amputations (n 5 14), and Syme or above
amputations (n 5 12). The average initial Wagner score
was 2.92 (range 1.0–4.0). Sixty-three patients (68.5%)
had healed DFUs by the longest follow-up. The average
initial A1C was 8.1% (range 4.8–13.6), and the average
ﬁnal A1C was 7.8% (range 4.8–13.1). Twenty-two patients (23.9%) were diagnosed with CRF.

PROMIS Scores
The mean initial PROMIS PF, PI, and depression scores
were 34.4 (range 19.1–53.1), 58.7 (range 38.7–76.5),
and 51.4 (range 34.2–78.9), respectively. The majority
of patients (57.6 and 76.5%, respectively) reported PI and
PF at least 2 SDs worse than the U.S. average (Figure 2).
Clinical variables that showed an association with PF
symptom severity included amputation type (x2 42.1,
P ,0.01) and CRF (x2 9.7, P 5 0.05). PI symptom severity
was associated with ulcer healing status (x2 12.2,
P ,0.01). No other clinical variables were signiﬁcantly
associated with PI, PF, or depression symptom severity.
At the ﬁnal follow-up, the mean PI score decreased by 0.1
(range –26.6 to 29.5), the mean PF score increased by
1.7 (range –23.2 to 25.4), and the mean depression score
increased by 0.2 (range –25.2 to 32.7) (Table 1). Most
patients did not achieve MCID in PF, PI, or depression from
the initial visit to the longest follow-up visit (47.8, 40.2,
and 46.7% remained the same, respectively). An improved MCID in PF, PI, or depression was noted in 33.7,
34.8, and 27.2% of patients, respectively. A decline equal
to or greater than an MCID in PF, PI, or depression was
noted in 18.5, 25.0 and 26.1% of patients, respectively
(Figure 3).

TABLE 1 Patient Demographics
Initial
(n 5 111)

Follow-Up >3 Months
(n 5 92)

62.2 (12.0), 33–96

60.52 (11.5), 33–96

88 (79.3)

74 (80.4)

33.8 (6.8), 22.0–57.5

34.1 (6.9), 22.0–57.5

Initial, mean (SD), range
PF
PI

34.5 (7.8), 19.1–53.1
58.9 (10.4), 38.7–77.8

34.4 (7.7), 19.1–53.1
58.7 (10.7), 38.7–76.5

Depression

51.1 (10.8), 34.2–78.9

51.4 (10.7), 34.2–78.9

Prognostic Factors
Patient factors
Age, mean (SD), range
Male sex, n (%)
BMI, mean (SD), range
Symptom severity (PROMIS scores)

Change from initial to longest follow-up, mean (SD), range
PF
PI

1.7 (8.9), –23.2 to 25.4
–0.1 (9.7), –26.6 to 29.5

Depression (n 5 83)

0.2 (8.9), –25.2 to 32.7

Clinical factors
Wagner score, mean (SD), range

2.92 (0.41), 1.0–4.0

A1C, %, mean (SD), range
Initial (n 5 78)
Latest follow-up (n 5 76)

8.1 (1.9), 4.8–13.6

Chronic renal failure, n (%)
Type of operative procedure, n (%)
Irrigation and debridement
Forefoot amputation Mid/
hind foot amputation Syme
or above amputation
Healed (yes), n (%)
Length of follow-up, months, mean (SD), range

Statistically signiﬁcant moderate correlations among
scales existed for PROMIS T-score values and symptom
severity at the initial visit. The strongest correlation was
noted between PI and depression (P ,0.01, Spearman r 5
0.44). x2 Analysis of PI and depression symptom severity
showed a signiﬁcant association (Table 2). The 2 3 2 table
revealed that patients who reported a PI .60 were more
likely to report depression. There was also a moderate to
poor correlation between PF and depression (P ,0.01,
r 5 0.39). x2 Analysis of PF and depression symptom
severity also showed a signiﬁcant association (Table 2).
The 2 3 2 table showed that patients who reported a low
PF were also more likely to report a depression score .50
(Table 2). The Spearman correlation between PF and PI
was moderate to poor (P ,0.01, r 5 –0.27), and the x2
analysis PI and PF symptom severity was also signiﬁcant. At the initial time point, as the MCID sum of PF
and PI increased, depression scores .50 decreased
(Table 3).

8.1 (1.9), 4.8–13.6
7.8 (1.9), 4.8–13.1
22 (23.9)

10 (9.0)
9 (8.1)
6 (5.4)

39
46
14
12
63

(42.4)
(50.0)
(15.2)
(13.0)
(68.5)

4.7 (1.9), 3–12

There were also signiﬁcant poor to moderate correlations
among changes in PROMIS scales and among MCID
change in PROMIS scales. The strongest correlation was
between change in PI and change in depression (P ,0.01,
r 5 0.47). x2 Analysis of MCID categories for PI and
depression also showed a signiﬁcant association
(P ,0.01). There was also a signiﬁcantly poor correlation
between MCID categories for PF and PI (P ,0.01, r 5
–0.28). x2 Analysis of PF and depression symptom severity
also showed a signiﬁcant association (Table 2). There was
no signiﬁcant correlation between MCID categories for PF
and depression (P 5 0.15, r 5 –0.15), and x2 analysis of
MCID categories for PF and depression showed signiﬁcant association (P 5 0.04). The correlation of the sum of
the change in PF and PI scores was signiﬁcant (P 5 0.02,
r 5 0.24), and x2 analysis showed a signiﬁcant association (P ,0.01) of MCID categories of depression with
the sum of categories of MCID change for PF and PI
(Table 4).

because of physical limitations caused by DFUs and resultant amputations (27–29). Amputation type (x2 42.1,
P ,0.01) and CRF (x2 9.7, P 5 0.05) were the only
clinical factors shown to affect PF.

FIGURE 2 Symptom severity by 1-SD increments across PROMIS
scales. Mean initial PROMIS PF, PI, and depression scores
assessed by SDs below the U.S. population average. High raw PI
T-scores were transformed into SDs lower than those of the
U.S. population.

Discussion
Despite having reduced sensation, many DFU patients
experience signiﬁcant pain. Our results indicate that the
pain perception of DFU patients is unlikely to change
despite successful operative intervention. PROMIS assessments demonstrate the potential to improve care by
allowing for better communication between patients and
providers, in addition to more reliable pain assessment
and valid data collection (11). The predictive nature of
PROMIS data are especially helpful in improving operative decisions and patient care (25). This is the ﬁrst study
to use PROMIS scores in an attempt to characterize the
pain experienced by DFU patients.
Our data showed that 75% of patients with infected DFUs
report signiﬁcant amounts of pain at initial presentation.
The average PI score of our cohort was 58.9, with most
patients reporting ~2 SDs above the U.S. average (Figure
2). Ulcer healing status was the only clinical factor that
was signiﬁcantly related to PI (x2 12.2, P ,0.01). Other
studies have found a similar percentage of patients with
diabetes (40–60%) reporting pain (4,6).

From the initial visit to longest follow-up visit, mean
changes in PI, PF, and depression were 1.7, –0.1, and 0.2,
respectively (Table 1). Around one-third of our cohort
showed an MCID improvement in PF, PI, or depression
after operative intervention. The majority of our patients
reported no change in PROMIS domains or sometimes
worse outcomes after treatment (Figure 3). This ﬁnding
indicates that operative intervention most likely did not
change pain perception in the cohort.
Elevated depression and PI were commonly reported
together (P ,0.01, Spearman r 5 0.44) at the initial time
point in our study. Those who reported PI .60 were more
likely to report depression .50 (Table 2). This observation is consistent with existing literature that also
observed the coexistence of patient-reported pain and
depression levels (4,30). Low PF and high PI scores were
also found to be coexisting (P ,0.01, r 5 –0.27) at the
initial time point. DFU patients signiﬁcantly reported both
depression and low PF (P ,0.01, r 5 0.39) at the initial
time point, and those who reported PF ,40 were more
likely to report depression (Table 2). Summing initial PF
and PI MCIDs revealed that patients who simultaneously
reported low PF and PI were more likely to report
depression (Table 3). This ﬁnding held true for MCID
assessment as well (Table 4).
MCID changes were statistically signiﬁcant between
depression and PI (P ,0.01) as well as PF and PI (P 5
0.02). On the other hand, MCID change for PF and

Surprisingly, the average reported depression score (51.4)
within the DFU population was not statistically signiﬁcantly higher than in the general U.S. population
(Table 1). Based on previous studies, we expected depression scores to be signiﬁcantly higher among people
with diabetes because of the bidirectional relationship
between type 2 diabetes and depression (26). No clinical
factors were signiﬁcantly correlated with depression.
Reported PF was primarily 1.5 SDs below that in the
average U.S. population (Figure 2). This was expected

FIGURE 3 Documenting change in patients with DFUs. Patients
are categorized by MCID improvement or decline from their initial
appointment to their longest follow-up visit.

Depression Score

TABLE 2 x2 Analysis of PI and Depression at Initial Time Point (P 5 0.001, Spearman r 5 0.49)
<50

PI Score
50–59.9

60–69.9

‡70

Total

<50

16 (14.4)

18 (16.2)

25 (22.5)

1 (0.9)

60 (54.1)

50–59.9

4 (4.5)

4 (3.6)

16 (14.4)

5 (4.5)

30 (27.0)

60–69.9

0 (0.0)

2 (1.8)

6 (5.4)

1 (0.9)

9 (8.1)

70–79.9

2 (1.8)

0 (0.0)

2 (1.8)

4 (3.6)

8 (7.2)

‡80

0 (0.0)

0 (0.0)

2 (1.8)

2 (1.8)

4 (3.6)

Total

23 (20.7)

24 (21.6)

51 (45.9)

13 (11.7)

111 (100.0)

Data are n (%). Bold type indicates statistical signiﬁcance.

depression was not statistically signiﬁcant (P 5 0.08).
Other clinical factors tested for MCID were initial A1C,
ﬁnal A1C, CRF, type of operative intervention (irrigation
and debridement, forefoot amputation, mid/hind foot
amputation, and Syme or above amputation), woundhealing status, and length of follow-up (Table 1). No
other clinical factors were found to be statistically
signiﬁcant for an MCID change (P .0.10).
Several methods are used for diagnosing DPN, with the
Semmes-Weinstein 5.07 (10G) monoﬁlament test being
the most prevalent among health care providers because
of its convenience and availability. However, monoﬁlament tests lack the standardization needed to conﬁrm the
range of nerve ﬁber damage, which can vary among
individuals (31). Differences in test application, interpretation, and populations all contribute to the low
speciﬁcity and sensitivity of the monoﬁlament test (2).
Ultimately, there is no universal standard for diagnosing
neuropathic pain. It has been suggested that more than
one test of neurological deﬁcits is required for the diagnosis of DPN; recommendations in the literature include using a combination of both clinical and diagnostic
testing (32,33). Screening tests such as the Neuropathy
Symptom and Change Score, Neuropathy Impairment
Score, and Michigan Neuropathy Screening Instrument
help with accurate and reliable diagnosis of DPN (34).
In our cohort of 111 patients, 48 were diagnosed with
DPN by the senior author, who performed the SemmesWeinstein 5.07 (10G) monoﬁlament test to diagnose
DPN. Fifty-ﬁve of our patients were previously diagnosed
with DPN by another physician (primary care provider,
neurologist, or endocrinologist). However, because of the
lack of diagnostic standardization and documentation,
we were not able to clearly conﬁrm the validity of DPN in
these patients. The remaining eight patients were not
formally diagnosed with DPN by the senior author or

another physician, although they were documented to
have reduced sensation at their appointments. Even
though there were generally higher levels of reported PI,
the patient-reported PROMIS data do not conclusively
point to painful DPN as the origin of the pain. Active
infections also may have played a role in aggravation of
DPN. For further research, using a patient-reported
PROMIS measure of neuropathic pain may provide
additional information to determine whether
experienced pain is related to painful DPN or a separate
comorbidity (35).
Studies have shown clinical depression to be present in
25% of patients with type 2 diabetes, and, as previously
noted, depression risk has been shown to double in
populations with diabetes (7,26). However, a previous
study also found that DFUs and depressive symptoms are
not signiﬁcantly related (33). The authors suggest that
patients with a depressed affect shared two major variables: a concern for the unpredictability and lack of
treatment for their condition and a change in social selfperception that is caused by a decrease in PF (33).
Because most of our cohort had low PF scores, a possible
ex-planation for the lack of depression might be related
to the ﬁrst variable. If DFU patients understood their
condition and treatment options, they might experience
less de-pression and anxiety about the outcome.
Screening study participants with the Patient Health
Questionnaire-9 or a social determinants of health
questionnaire may better assess the source of patientreported depression (36–38).
In terms of postoperative care, our results indicate that
DFU patients’ pain does not decrease postoperatively,
suggesting that an opioid prescription is unlikely to beneﬁt
patients with DPN pain. Neuromodulating drugs such as
amitriptyline, duloxetine, pregabalin, or gabapentin may
be considered as initial treatment (39). Additionally, the
DFU patient population appears to be particularly at risk

TABLE 3 x2 Analysis of PF and Depression at Initial Time Point (P 5 0.007, Spearman r 5 0.41)

Depression Score

PF Score
<20

20–29.9

30–39.9

40–49.9

‡50

Total

<50

0 (0.0)

7 (6.3)

30 (27.0)

18 (16.2)

5 (4.5)

60 (54.1)

50–59.9

3 (2.7)

11 (9.9)

13 (11.7)

3 (2.7)

0 (0.0)

30 (27.0)

60–69.9

0 (0.0)

5 (4.5)

4 (3.6)

0 (0.0)

0 (0.0)

9 (8.1)

70–79.9

0 (0.0)

4 (3.6)

4 (3.6)

0 (0.0)

0 (0.0)

8 (7.2)

‡80

0 (0.0)

2 (1.8)

2 (1.8)

0 (0.0)

0 (0.0)

4 (3.6)

Total

3 (2.7)

29 (26.1)

53(47.7)

21 (18.9)

5 (4.5)

111(100.0)

Data are n (%). Bold type indicates statistical signiﬁcance.

This study is limited by its small sample size and lack of
clinical variables assessed in the cohort. Despite initially
recruiting 240 participants, only 111 were included in
initial patient characteristic analyses, and 92 were included in further analyses of changes in PROMIS
domains. The 111 patients met all inclusion criteria
except for the criterion of 3-month postoperative followup. All analyses that identiﬁed change from the initial
visit to the longest follow-up visit were conducted with
the 92 participants who met all inclusion criteria and had
at a minimum of 3 months of postoperative follow-up.
Demographic data such as race, ethnicity, and socioeconomic status were not included in the data analyses
and could confound study results (2). Additionally, acknowledging that DFU patients often have multiple
comorbidities, only a small number of possible diagnoses
were used in analyses.
We chose a short follow-up duration to limit the confounding variables associated with multiple interventions. The longer the follow-up period, the more patients
returned with recurrent DFUs at the same or different
locations that required further operative interventions. To
isolate the clinical analysis to a single operative event, we
limited our follow-up to a 3- to 12-month period. Those
who required an additional procedure within the time
frame were excluded from the study.

Our average healing rate (68.5%) falls in the middle of
those found in other studies, which have ranged from 33
to .80%, but studies have also shown that the average
healing time is .2 months or, for uncomplicated cases,
within 3 months (1,3). Although we found that
depression in the DFU population was only slightly
higher than in the general U.S. population (score of
51.4), this ﬁnding could be confounded by a short followup period. Studies have shown that patients with
complications have higher depression rates (7).
Therefore, if the follow-up
time frame had been longer in this study, higher
depression levels could have been observed as more
complications arose.

Conclusion
Our results show that PF, PI, and depression rates are
likely to remain the same even after the successful healing
of a DFU. In addition, PROMIS symptoms tended to occur
TABLE 4 x2 Analysis of MCID PF and PI Sum Versus MCID
for Depression

Depression (1-SD Intervals)

PF and PI Sum (1-SD Intervals)

for opioid abuse based on shared risk factors such as
preoperative pain, depression, and low socioeconomic
status (40). Studies have shown that benzodiazepine and
antidepressant usage preoperatively puts patients at
greater risk for opioid abuse postoperatively (40,41).
Not only is there a chance of opioid abuse, but higher
opioid dosages are also associated with increased complications, less satisfaction, and a greater pain intensity
postoperatively (42,43).

–1

0

1

Total

–2

5

3

0

8

–1

4

6

4

14

0

13

17

3

33

1

1

3

1
7

21

2

1

4

1

1 16

Total

24

43

25

92

Scores are separated by 1-SD intervals from the U.S. average, where –2
indicates a deterioration in both PF and PI and 12 indicates an improvement
in both. Patients are totaled on the far right column and bottom row.

together, suggesting that providers should consider
multidimensional assessment when attempting to address
patients’ needs. Continuing to investigate this challenging
patient population will allow for improvement in the
physical and psychological functioning of patients
with DFUs.
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